Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.62 |
| ▸ | ULK1 | O75385 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037237 | 0.92 | EGFR (0.60) | EGFRULK1PTK2GLO1ALK | |
| SCHEMBL1034549 | 0.90 | ULK1 (0.73) | EGFRULK1PTK2GLO1MAPK8 | |
| SCHEMBL12726558 | 0.89 | EGFR (0.53) | EGFRULK1PTK2MAPK8MAPK9 | |
| SCHEMBL1038417 | 0.89 | ZAP70 (0.54) | EGFRULK1PTK2GLO1MAPK8 | |
| SCHEMBL1034753 | 0.88 | GLO1 (0.70) | EGFRPTK2GLO1MAPK8MAPK9 | |
| SCHEMBL1707870 | 0.88 | EGFR (0.69) | EGFRULK1PTK2ZAP70 | |
| SCHEMBL1036482 | 0.87 | GLO1 (0.64) | EGFRULK1PTK2GLO1MAPK8 | |
| SCHEMBL9911241 | 0.86 | EGFR (0.69) | EGFRULK1PTK2ALKCDK19 | |
| SCHEMBL1039787 | 0.86 | EGFR (0.59) | EGFRULK1PTK2GLO1ALK | |
| Hydrochloric Acid SCHEMBL1708532 | 0.85 | EGFR (0.68) | EGFRULK1PTK2ALKCDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | EGFR 2061/4885ULK1 4345/4885PTK2 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.